IFNB1 and myeloid sarcoma: Furthermore, while interferon-β (IFN-β), a relapsing–remitting MS drug, suppressed disease development in the vehicle-loaded A-NP-treated mice, mice treated with exemestane-loaded A-NP did not respond to IFN-β treatment (Fig. 4D).